Francesco Perri

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1513391/publications.pdf

Version: 2024-02-01

		3	304368	32	29751	
82	1,635	5	22		37	
papers	citation	S	h-index		g-index	
83	83		83		2913	
03	03		03		2713	
all docs	docs citat	ions	times ranked		citing authors	

#	Article	IF	CITATIONS
1	A SARS-CoV-2 Infection High-Uptake Program on Healthcare Workers and Cancer Patients of the National Cancer Institute of Naples, Italy. Healthcare (Switzerland), 2022, 10, 205.	1.0	O
2	Clinical and Molecular Characteristics of Rare Malignant Tumors of Colon and Rectum. Biology, 2022, 11, 267.	1.3	8
3	Radiomics Metrics Combined with Clinical Data in the Surgical Management of Early-Stage (cT1–T2 N0) Tongue Squamous Cell Carcinomas: A Preliminary Study. Biology, 2022, 11, 468.	1.3	8
4	VOSviewer-Based Bibliometric Network Analysis for Evaluating Research on Juvenile Primary Fibromyalgia Syndrome (JPFS). Children, 2022, 9, 637.	0.6	16
5	New Challenges in Evaluating Outcomes after Immunotherapy in Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma. Vaccines, 2022, 10, 885.	2.1	2
6	Tumour Burden Reporting in Phase III Clinical Trials of Metastatic Lung, Breast, and Colorectal Cancers: A Systematic Review. Cancers, 2022, 14, 3262.	1.7	3
7	Newâ€generation anticancer drugs and medicationâ€related osteonecrosis of the jaw (MRONJ): Late onset 3Âyears after ipilimumab endovenous administration with a possible role of target therapy. Clinical Case Reports (discontinued), 2021, 9, 61-66.	0.2	7
8	KRAS Mutational Regression Is Associated With Oligo-Metastatic Status and Good Prognosis in Metastatic Colorectal Cancer. Frontiers in Oncology, 2021, 11, 632962.	1.3	9
9	Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck: A Big and Intriguing Challenge Which May Be Resolved by Integrated Treatments Combining Locoregional and Systemic Therapies. Cancers, 2021, 13, 2371.	1.7	35
10	Electrochemotherapy as a First Line Treatment in Recurrent Squamous Cell Carcinoma of the Oral Cavity and Oropharynx PDL-1 Negative and/or with Evident Contraindication to Immunotherapy: A Randomized Multicenter Controlled Trial. Cancers, 2021, 13, 2210.	1.7	6
11	Prognostic Significance of CXCR4 in Colorectal Cancer: An Updated Meta-Analysis and Critical Appraisal. Cancers, 2021, 13, 3284.	1.7	8
12	Malignant Sinonasal Tumors: Update on Histological and Clinical Management. Current Oncology, 2021, 28, 2420-2438.	0.9	19
13	Addendum: Perri et al. Electrochemotherapy as a First Line Treatment in Recurrent Squamous Cell Carcinoma of the Oral Cavity and Oropharynx PDL-1 Negative and/or with Evident Contraindication to Immunotherapy: A Randomized Multicenter Controlled Trial. Cancers 2021, 13, 2210. Cancers, 2021, 13, 3412.	1.7	O
14	Translational Insights and New Therapeutic Perspectives in Head and Neck Tumors. Biomedicines, 2021, 9, 1045.	1.4	4
15	Prospective Evaluation of Radiotherapy-Induced Immunologic and Genetic Effects in Colorectal Cancer Oligo-Metastatic Patients with Lung-Limited Disease: The PRELUDE-1 Study. Cancers, 2021, 13, 4236.	1.7	8
16	Patients affected by squamous cell carcinoma of the head and neck: A population particularly prone to developing severe forms of COVID‹19. Experimental and Therapeutic Medicine, 2021, 22, 1298.	0.8	1
17	Pre-Treatment Neutrophil-to-Lymphocyte and Platelet-to-Lymphocyte Ratios as Predictors of Occult Cervical Metastasis in Clinically Negative Neck Supraglottic and Clottic Cancer. Journal of Personalized Medicine, 2021, 11, 1252.	1.1	2
18	Absolute basophil count is associated with time to recurrence in patients with high-grade T1 bladder cancer receiving bacillus Calmette–Guérin after transurethral resection of the bladder tumor. World Journal of Urology, 2020, 38, 143-150.	1.2	49

#	Article	IF	Citations
19	Immune Response Against Head and Neck Cancer: Biological Mechanisms and Implication on Therapy. Translational Oncology, 2020, 13, 262-274.	1.7	49
20	Boosting the Immune Response with the Combination of Electrochemotherapy and Immunotherapy: A New Weapon for Squamous Cell Carcinoma of the Head and Neck?. Cancers, 2020, 12, 2781.	1.7	16
21	Evolution of Mutational Landscape and Tumor Immune-Microenvironment in Liver Oligo-Metastatic Colorectal Cancer. Cancers, 2020, 12, 3073.	1.7	28
22	COVID-19 Emergency and Post-Emergency in Italian Cancer Patients: How Can Patients Be Assisted?. Frontiers in Oncology, 2020, 10, 1571.	1.3	14
23	Management of Ewing Sarcoma Family of Tumors: A Short Description of a Rare Primitive Uterine pPNET and Literature Review. OncoTargets and Therapy, 2020, Volume 13, 1179-1184.	1.0	2
24	Genetic trajectory and immune microenvironment of lung-specific oligometastatic colorectal cancer. Cell Death and Disease, 2020, 11, 275.	2.7	21
25	Management of HPV-Related Squamous Cell Carcinoma of the Head and Neck: Pitfalls and Caveat. Cancers, 2020, 12, 975.	1.7	30
26	Oral lichen planus and other confounding factors in narrow band imaging (NBI) during routine inspection of oral cavity for early detection of oral squamous cell carcinoma: a retrospective pilot study. BMC Oral Health, 2019, 19, 70.	0.8	16
27	<p>Management of recurrent nasopharyngeal carcinoma: current perspectives</p> . OncoTargets and Therapy, 2019, Volume 12, 1583-1591.	1.0	72
28	Electrochemotherapy as palliative treatment in patients with advanced head and neck tumours: Outcome analysis in 93 patients treated in a single institution. Oral Oncology, 2019, 92, 77-84.	0.8	14
29	Clinical management of localized undifferentiated sinonasal carcinoma. Anti-Cancer Drugs, 2019, 30, 308-312.	0.7	5
30	Genetics and management of locally advanced carcinomas of the head and neck: role of altered fractionation radiotherapy. Future Science OA, 2019, 5, FSO347.	0.9	6
31	Translational Research: A Future Strategy for Managing Squamous Cell Carcinoma of the Head and Neck?. Anti-Cancer Agents in Medicinal Chemistry, 2019, 18, 1220-1227.	0.9	10
32	Metastatic <scp>HPV</scp> â€related oropharyngeal carcinoma cured with chemoradiotherapy: importance of pretherapy biomolecular assessment. Clinical Case Reports (discontinued), 2018, 6, 56-62.	0.2	5
33	Thyroid cancer management. Anti-Cancer Drugs, 2018, 29, 483-490.	0.7	14
34	Isoquercetin as an Adjunct Therapy in Patients With Kidney Cancer Receiving First-Line Sunitinib (QUASAR): Results of a Phase I Trial. Frontiers in Pharmacology, 2018, 9, 189.	1.6	26
35	Melanoma Adjuvant Treatment: Current Insight and Clinical Features. Current Cancer Drug Targets, 2018, 18, 442-456.	0.8	5
36	Optimal Management of Prostate Cancer Based on its Natural Clinical History. Current Cancer Drug Targets, 2018, 18, 457-467.	0.8	10

#	Article	IF	Citations
37	Translational Research in Cutaneous Melanoma: New Therapeutic Perspectives. Anti-Cancer Agents in Medicinal Chemistry, 2018 , 18 , $166-181$.	0.9	10
38	Effective nivolumab sequential thoracic radiotherapy in elderly patients with advanced squamous cell lung cancer: did radiation therapy play a role? A case report. OncoTargets and Therapy, 2018, Volume 11, 4621-4629.	1.0	6
39	The Impact of Translational Research in Breast Cancer Care: Can we Improve the Therapeutic Scenario?. Anti-Cancer Agents in Medicinal Chemistry, 2018, 18, 832-836.	0.9	3
40	Epigenetic control of gene expression: Potential implications for cancer treatment. Critical Reviews in Oncology/Hematology, 2017, 111, 166-172.	2.0	113
41	Locally advanced paranasal sinus carcinoma: A study of 30 patients. Oncology Letters, 2017, 13, 1338-1342.	0.8	8
42	Optimal multidisciplinary treatment of oral cavity mucosal melanoma. Anti-Cancer Drugs, 2017, 28, 327-334.	0.7	3
43	Predictive parameters in hypofractionated whole-breast 3D conformal radiotherapy according to the Ontario Canadian trial. OncoTargets and Therapy, 2017, Volume 10, 1835-1842.	1.0	14
44	Single nucleotide polymorphisms and unacceptable late toxicity in breast cancer adjuvant radiotherapy: a case report. Breast Cancer: Targets and Therapy, 2017, Volume 9, 401-406.	1.0	1
45	Oral vinorelbine: a feasible and safe partner for radiotherapy in the treatment of locally advanced non-small cell lung cancer. OncoTargets and Therapy, 2016, 9, 2359.	1.0	8
46	P53 mutations and cancer: a tight linkage. Annals of Translational Medicine, 2016, 4, 522-522.	0.7	79
47	Phase II clinical study of valproic acid plus cisplatin and cetuximab in recurrent and/or metastatic squamous cell carcinoma of Head and Neck-V-CHANCE trial. BMC Cancer, 2016, 16, 918.	1.1	60
48	Concomitant cetuximab and radiation therapy: A possible promising strategy for locally advanced inoperable non-melanoma skin carcinomas. Molecular and Clinical Oncology, 2016, 4, 467-471.	0.4	15
49	The evolving landscape in advanced penile cancer. Future Science OA, 2015, 1, FSO9.	0.9	3
50	Epstein–Barr virus infection and nasopharyngeal carcinoma. Anti-Cancer Drugs, 2015, 26, 1017-1025.	0.7	17
51	<scp>B</scp> rookeâ€ <scp>S</scp> piegler syndrome presenting multiple concurrent cutaneous and parotid gland neoplasms: Cytologic findings on fineâ€needle sample and description of a novel mutation of the <scp>CYLD</scp> gene. Diagnostic Cytopathology, 2015, 43, 654-658.	0.5	11
52	Adjuvant treatment in patients at high risk of recurrence of thymoma: efficacy and safety of a three-dimensional conformal radiation therapy regimen. OncoTargets and Therapy, 2015, 8, 1345.	1.0	6
53	How can we improve prognostic models in renal cell carcinoma?. Expert Opinion on Pharmacotherapy, 2015, 16, 1281-1283.	0.9	3
54	Radioresistance in head and neck squamous cell carcinoma: Biological bases and therapeutic implications. Head and Neck, 2015, 37, 763-770.	0.9	105

#	Article	IF	Citations
55	Targeted therapy: A new hope for thyroid carcinomas. Critical Reviews in Oncology/Hematology, 2015, 94, 55-63.	2.0	39
56	Carcinomas of the Head and Neck. , 2015, , 605-627.		0
57	Ipilimumab in the treatment of metastatic melanoma: management of adverse events. OncoTargets and Therapy, 2014, 7, 203.	1.0	87
58	Carboplatin plus etoposide in heavily pretreated castration-resistant prostate cancer patients. Future Oncology, 2014, 10, 1353-1360.	1.1	23
59	ASCO 2013: bevacizumab and glioblastoma – a marriage dissolution?. Current Medical Research and Opinion, 2014, 30, 1871-1873.	0.9	4
60	Hyalinizing clear cell carcinoma of the parotid gland: Report of a recurrent case with aggressive cytomorphology and behavior diagnosed on fineâ€needle cytology sample. Diagnostic Cytopathology, 2014, 42, 63-68.	0.5	23
61	The best partner for radiotherapy after induction chemotherapy in a larynx preservation strategy. Oral Oncology, 2014, 50, e1-e2.	0.8	3
62	HPV-related oropharyngeal cancers: From pathogenesis to new therapeutic approaches. Cancer Letters, 2014, 351, 198-205.	3.2	37
63	Optimal management of a patient with recurrent nasopharyngeal carcinoma. World Journal of Clinical Cases, 2014, 2, 297.	0.3	8
64	Calcitriol: a better option than vitamin D in denosumab-treated patients with kidney failure?. Expert Opinion on Biological Therapy, 2013, 13, 149-151.	1.4	16
65	Induction Chemotherapy with Docetaxel, Cisplatin and Capecitabine, Followed by Combined Cetuximab and Radiotherapy in Patients with Locally Advanced Inoperable Squamous Cell Carcinoma of the Head and Neck: A Phase I-II Study. Oncology, 2013, 84, 251-254.	0.9	4
66	Combined chemo-radiotherapy in locally advanced nasopharyngeal carcinomas. World Journal of Clinical Oncology, 2013, 4, 47.	0.9	11
67	Treatment Approaches in Elderly Patients with Head and Neck Cancer. Anti-Cancer Agents in Medicinal Chemistry, 2013, 13, 1383-1390.	0.9	11
68	Multidisciplinary Approach to Patient with Malignant Melanoma. Anti-Cancer Agents in Medicinal Chemistry, 2013, 13, 887-900.	0.9	3
69	Integrated Therapeutic Approaches in Head and Neck Cancer: The Importance of Multidisciplinary Team Management. Anti-Cancer Agents in Medicinal Chemistry, 2013, 13, 834-843.	0.9	15
70	Multidisciplinary Approach to Rectal Cancer: Are we Ready for Selective Treatment Strategies?. Anti-Cancer Agents in Medicinal Chemistry, 2013, 13, 852-860.	0.9	14
71	Non-AIDS-related Kaposi's sarcoma: A single-institution experience. World Journal of Clinical Oncology, 2013, 4, 52.	0.9	8
72	Neoadjuvant chemo-radiotherapy for patients with borderline resectable pancreatic cancer: a meta-analytical evaluation of prospective studies. JOP: Journal of the Pancreas, 2013, 14, 618-25.	1.5	24

#	Article	IF	CITATIONS
73	Induction docetaxel-cisplatin followed by extended-field radiotherapy in patients with cervical metastases from unknown primary carcinoma. Anticancer Research, 2013, 33, 1135-9.	0.5	5
74	Anaplastic thyroid carcinoma: A comprehensive review of current and future therapeutic options. World Journal of Clinical Oncology, 2011, 2, 150.	0.9	86
75	Targeted – Therapy and Imaging Response: A New Paradigm For Clinical Evaluation?. Reviews on Recent Clinical Trials, 2011, 6, 259-265.	0.4	18
76	Locally advanced nasopharyngeal carcinoma: Current and emerging treatment strategies. World Journal of Clinical Oncology, 2011, 2, 377.	0.9	36
77	Treatment approaches to nasopharyngeal carcinoma: a review. Anti-Cancer Drugs, 2010, 21, 471-477.	0.7	86
78	Pre-operative chemotherapy for colorectal cancer liver metastases: an update of recent clinical trials. Cancer Chemotherapy and Pharmacology, 2010, 66, 209-218.	1.1	23
79	Recent results of cetuximab use in the treatment of squamous cell carcinoma of the head and neck. OncoTargets and Therapy, 2009, 2, 243.	1.0	5
80	Docetaxel in the management of head and neck cancer. Anti-Cancer Drugs, 2009, 20, 639-645.	0.7	13
81	New treatment approaches in renal cell carcinoma. Anti-Cancer Drugs, 2009, 20, 893-900.	0.7	35
82	Efficacy and Safety of Tranexamic Acid in Cancer Surgery. An Update of Clinical Findings and Ongoing Research. Journal of Multidisciplinary Healthcare, 0, Volume 15, 1427-1444.	1.1	4